Phase 1 Study of Galinpepimut-S and Nivolumab Meets Primary End Point in MPM

Retrieved on: 2024-01-02 21:12:12

Tags for this article:

Orphan drugs

Antineoplastic drugs

Infectious causes of cancer

Nivolumab

Mesothelioma

Progression-free survival

Clinical endpoint

Zabadinostat

Serum B-cell maturation antigen

Click the tags to see associated articles and topics

Phase 1 Study of Galinpepimut-S and Nivolumab Meets Primary End Point in MPM. View article details on hiswai:

Excerpt

For patients who did not have an immune response to galinpepimut-S, only 1 patient (14.3%) had an objective response. Among all patients, the median ...

Article found on: www.targetedonc.com

View Original Article